BioWorld

May 24, 2007

Public Offering Generates $163M In Cash For Advanced Magnetics

Awaiting results from the final of four pivotal studies of its iron replacement therapeutic ferumoxytol, Cambridge, Mass.-based Advanced Magnetics Inc. is raising $162.9 million. (BioWorld Today) Read More

Cypress Shares Soar On Positive Phase III Data In Fibromyalgia

Vion Halts Phase III AML Trial, Causing Stock Drop

NewCo News: Arete Completes $51M Round For New Hypertension Class

Sirtris Increases Shares, Raises $60M In IPO For Sirtuin Work

Pivotal PolyHeme Trial Fails To Hit Endpoints, Hurting Northfield

Other News To Note

U.S. Patent Disclosures

Clinic Roundup

Today's news in brief

BioWorld

IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

BioWorld Science

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...

TL1A is overexpressed in hidradenitis suppurativa

BioWorld Science

Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...

Illustration of head with maze that is missing parts

Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke

BioWorld Science

Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...

VST Bio’s VB-001 is neuroprotector after stroke

BioWorld Science

At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...